Gemcitabine and epirubicin in patients with metastatic breast cancer: A phase I/II study

Breast

Volumn 15, Issue 5, 2006, Pages 601-609

  Campone, Mario ^a   Fumoleau, Pierre ^a   Viens, Patrice ^b   Diéras, Véronique ^c   Pujade Lauraine, Eric ^d   Serin, Daniel ^e   Petit, Thierry ^f   Espié, Marc ^g   Kayitalire, Louis ^h   Bozec, Laurence ^h   Pouillart, Pierre ^c  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSTITUT PAOLI CALMETTES   (France)

^c INSTITUT CURIE   (France)

^d HÔTEL DIEU   (France)

^e INSTITUT SAINTE CATHERINE   (France)

^f CENTRE PAUL STRAUSS   (France)

^g SAINT LOUIS HOSPITAL   (France)

^h Eli Lilly   (France)

Author keywords

Epirubicin; Gemcitabine; Metastatic breast cancer; Phase I II study

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GEMCITABINE; HORMONE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BREAST CANCER; BREAST SURGERY; BRONCHOPNEUMONIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPERIENCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLU LIKE SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOLOGIC DISEASE; HUMAN; INFECTION; LEUKOPENIA; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SEPTIC SHOCK; THROMBOCYTOPENIA; TIME; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 33749684974     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2005.11.010     Document Type: Article

References (36)

1. Cersosimo R.J., and Hong W.K. Epirubicin: a review on the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol 4 (1986) 425-439
2. Campora E., Nobile M.T., Sertoli M.R., et al. Phase II study of 4′-epi-doxorubicin in advanced breast cancer. Cancer Treat Rep 68 (1984) 1285-1286 (abstract)
3. Perez D.J., Harvey V.J., Robinson B.A., et al. A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 9 (1991) 2148-2152
4. Eksborg S., Hardell L., Bengtsson N.O., et al. Epirubicin as single agent therapy for the treatment of breast cancer-a pharmacokinetic and clinical study. Med Oncol Tumor Pharmacother 9 (1992) 75-80
5. Sledge G., Roth B., Munshi N., et al. High-dose epirubicin (EPI) as initial therapy for advanced breast cancer. Proc Am Soc Clin Oncol 11 (1992) 85 (abstract)
6. Habeshaw T., Paul J., James R., et al. Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial. J Clin Oncol 9 (1991) 295-304
7. Dogliotti L., Berruti A., Buniva T., et al. Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol 14 (1996) 1165-1172
8. French Epirubicin Study Group. A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. J Clin Oncol 6 (1988) 679-688
9. Buzdar A.U., Asmar L., and Hortobagyi G.N. Impact of patient characteristics on treatment outcome: anthracycline resistance. Eur J Cancer 33 Suppl 7 (1997) S3-S6
10. Porkka K., Blomqvist C., Rissamen P., et al. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin and cyclophosphamide for advanced breast cancer. J Clin Oncol 12 (1994) 1639-1647
11. Rahman Z.U., Frye D.K., Smith T.L., et al. Results and long-term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 85 (1999) 104-111
12. Carmichael J., Possinger K., Phillip P., et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13 (1995) 2731-2736
13. Anderson H., Lund B., Bach F., et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 12 (1994) 1821-1826
14. Casper E.S., Green M.R., Kelsen D.P., et al. Phase II trial of gemcitabine (2′2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12 (1994) 29-34
15. Lorusso V., Pollera C.F., Antimi M., et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Eur J Cancer 34 (1998) 1208-1212
16. Lund B., Hansen O.P., Theilade K., et al. Phase II study of gemcitabine (2′2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86 (1994) 1530-1533
17. Green M.R. Gemcitabine safety overview. Sem Oncol 23 5, Suppl 10 (1996) 32-35
18. Plunkett W., Huang P., Searcy C.E., et al. Gemcitabine: pharmacology and mechanisms of action. Sem Oncol 23 5, Suppl 10 (1996) 3-15
19. Blackstein M., Vogel C.L., Ambinder R., et al. Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial. Oncology 62 (2002) 2-8
20. Possinger K., Kaufmann M., Coleman R., et al. Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anticancer Drugs 10 (1999) 155-162
21. Brodowicz T., Köstler W., Möslinger R., et al. Single-agent gemcitabine or docetaxel as second- and third-line treatment of metastatic breast cancer: results of a retrospective analysis of two phase II trials. Breast 9 (2000) 338-342
22. Spielmann M., Llombart-Cussac A., Kalla S., et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 60 (2001) 303-307
23. Valerio M.R., Cicero G., Armata M.G., et al. Gemcitabine (G) in pretreated breast cancer (BC). Proc Am Soc Clin Oncol 20 (2001) 51b (abstract 1953)
24. Gerson R., Serrano-O A., Villalobos A., et al. Gemcitabine response in advanced breast cancer in relation to immunohistochemical factors. Proc Am Soc Clin Oncol 19 (2000) 145a (abstract 572)
25. Schmid P., Akrivakis K., Flath B., et al. Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer. Anticancer Drugs 10 (1999) 625-631
26. Berton-Rigaud D., Viens P., Dieras V., et al. Gemzar (G) and epirubicin (E) in patients with metastatic breast cancer (MBC): final results of a phase I dose finding study. Proc Am Soc Clin Oncol 19 (2000) 112a (abstract 433)
27. Campone M., Viens P., Dieras V., et al. Gemzar (G) and epirubicin (E) in patients (pts) with metastatic breast cancer (MBC): results of a phase II trial. Proc Am Soc Clin Oncol 20 (2001) 48b (abstract 1940)
28. Conte P.F., Bengala R., Danesi R., et al. Gemcitabine, epirubicin and paclitaxel (GET) in metastatic breast cancer (MBC): preliminary report of a phase I/II study with pharmacokinetic and peripheral blood progenitor cell (PBPC) mobilization assessment. Proc Am Soc Clin Oncol 17 (1998) 134a (abstract 511)
29. Conte P., Bengala S., Donati S., et al. Gemcitabine, epirubicin and taxol (GET) followed by high-dose chemotherapy (HDCT): high activity with good tolerability in metastatic breast cancer patients. Proc Am Soc Clin Oncol 18 (1999) 118a (abstract 449)
30. Luftner D., Flath B., Akrivakis C., et al. Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Invest New Drugs 16 (1998) 141-146
31. Perez-Manga G., Lluch A., Alba E., et al. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol 18 (2000) 2545-2552
32. Gomez H., Kahatt C., Falcon S., et al. A phase II study of neoadjuvant gemcitabine plus doxorubicin in stage IIIB breast cancer: a preliminary report. Sem Oncol 28 3, Suppl 10 (2001) 57-61
33. Silva A., Gonzalez H., Perez M., et al. Neoadjuvant gemcitabine plus epirubicin in locally advanced breast cancer: evidence of activity in a phase II study. Proc Am Soc Clin Oncol 21 (2002) 51b (abstract 2015)
34. Hausmaninger H., Morach G., Heinrich B., et al. Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study. Am J Clin Oncol 27 (2004) 429-435
35. Mazzoni F., Donati S., Gennari A., et al. A multicentric phase II trial of gemcitabine plus epirubicin plus taxol (GET) as first line chemotherapy for metastatic breast cancer. Breast Cancer Res Treat 64 (2000) 87 (abstract 347)
36. Sanchez-Rovira P., Jaen A., Gonzalez E., et al. Biweekly gemcitabine, doxorubicin, and paclitaxel as first-line treatment in metastatic breast cancer: final results from a phase II trial. Oncology 15 2, Suppl 3 (2001) 44-47